Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

8.9%

13 terminated/withdrawn out of 146 trials

Success Rate

90.8%

+4.3% vs industry average

Late-Stage Pipeline

29%

42 trials in Phase 3/4

Results Transparency

27%

35 of 129 completed trials have results

Key Signals

1 recruiting35 with results9 terminated4 withdrawn

Enrollment Performance

Analytics

Phase 1
87(64.0%)
Phase 3
36(26.5%)
N/A
6(4.4%)
Phase 4
6(4.4%)
Phase 2
1(0.7%)
136Total
Phase 1(87)
Phase 3(36)
N/A(6)
Phase 4(6)
+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (146)

Showing 20 of 146 trials
NCT01733082Recruiting

The Mycophenolate Pregnancy Registry

Role: collaborator

NCT06153238Phase 1Completed

A PK Study to Compare GME751 (Proposed Pembrolizumab Biosimilar) and US-licensed and EU-authorized Keytruda® in Participants With Stage II and III Melanoma

Role: lead

NCT06847724Phase 3Active Not Recruiting

Comparative PK, PD, Efficacy, and Safety Assessment of the Proposed Ocrelizumab Biosimilar CYB704 and Ocrevus in Participants With Relapsing Multiple Sclerosis

Role: lead

NCT07223294Phase 3Withdrawn

Study to Evaluate the Therapeutic Equivalence and Safety of Fluticasone Furoate and Vilanterol Inhalation Powder 100 mcg/25 mcg and BREO ELLIPTA 100 mcg/25 mcg in Participants With Asthma

Role: lead

NCT06159790Phase 3Completed

A Study to Compare Efficacy, Safety, and Immunogenicity of GME751 and EU-authorized Keytruda in Adult Participants With Untreated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)

Role: lead

NCT06587451Phase 3Terminated

Integrated Pharmacokinetics (PK)/Efficacy, Safety, and Immunogenicity Study to Demonstrate Similarity of JPB898, a Proposed Biosimilar to Nivolumab, to Opdivo® in Combination With Yervoy®

Role: lead

NCT05633771Active Not Recruiting

Observational Study, to Assess Treatment Retention of an Adalimumab Biosimilar (Hyrimoz®) in IBD Patients in Real Life Setting

Role: lead

NCT05258747Phase 1Completed

A Crossover Bioequivalence Study of Olaparib Tablets, 150 mg (Lek Pharmaceuticals d.d.) and Lynparza® (Olaparib) Tablets 150 mg (AstraZeneca Pharmaceuticals LP), in Patients With Breast Cancer Gene (BRCA) Mutated Ovarian Cancer, Recurrent Ovarian Cancer or Metastatic Breast Cancer

Role: lead

NCT05070650Phase 3Withdrawn

Efficacy and Safety of the Combination of Acetylcysteine, Paracetamol and Phenylephrine for the Treatment of Common Cold

Role: lead

NCT01766934Completed

Non-interventional, Long-term Safety Data Collection of Zarzio® / Filgrastim HEXAL® in Stem Cell Donors

Role: lead

NCT04864834Phase 3Completed

Phase III Study Assessing the Efficacy, Safety and Immunogenicity of SOK583A1 Versus Eylea® in Patients With Neovascular Age-related Macular Degeneration

Role: lead

NCT00537914Phase 4Completed

Safety and Efficacy of Omnitrope® (rhGH) in Short Children Born Small for Gestational Age (SGA)

Role: lead

NCT05887843Phase 1Terminated

Study to Compare the Pharmacokinetics of Fixed-Dose Combination of Mometasone + Azelastine Nasal Spray to Mometasone and Azelastine Nasal Sprays in Adolescents and Young Adults With Seasonal Allergic Rhinitis

Role: lead

NCT05590598Phase 3Completed

Efficacy and Safety of Azelastine +Mometasone , Nasal Spray, 140 mcg + 50 mcg, (Sandoz d.d., Slovenia) and Momat Rino Advance, Nasal Spray, 140 mcg + 50 mcg, (Glenmark, India) Administered as a Monotherapy to Patients With Seasonal Allergic Rhinitis.

Role: lead

NCT05588804Phase 3Completed

Study of the Efficacy and Safety of Broncho-munal®, Capsules, 7 mg for the Treatment of Acute Uncomplicated Respiratory Tract Infections

Role: lead

NCT05311475Phase 3Completed

Prospective, Randomized, Multinational, Multicenter, Double-blind, Placebo and Active Controlled Trial in 4 Parallel-groups of Patients Suffering From Seasonal Allergic Rhinitis

Role: lead

NCT00666835Phase 3Completed

Study to Evaluate the Efficacy and Safety of HX575 Hexal AG vs ERYPO® for the Treatment of Anemia in Hemodialysis Patients

Role: lead

NCT04085809Not ApplicableCompleted

This Was a Clinical Study Investigating the Moisturization and Desquamation Effect of AmLactin® Rapid Relief Restoring Lotion + Ceramides on Dry Skin in Healthy Female Volunteers. AmLactin® Rapid Relief is an Over-the-counter Cosmetic

Role: lead

NCT05282004Phase 3Completed

Study of the Safety of Use of Intravitreal SOK583A1 Provided in a Vial Kit

Role: lead

NCT03974100Phase 3Completed

Study Investigating PK, PD, Efficacy, Safety, and Immunogenicity of Biosimilar Denosumab (GP2411) in Patients With Postmenopausal Osteoporosis

Role: lead